Hepalink Group, established in 1998 in Shenzhen, is a leading multinational pharmaceutical company that focuses on addressing unmet clinical needs by providing high-quality, safe, and effective medications and services globally. The company operates across a comprehensive heparin supply chain, which includes the production of heparin raw materials and finished products, as well as the development and commercialization of innovative drugs. Hepalink has a strong presence in over 40 countries and regions, emphasizing its commitment to delivering healthcare solutions that benefit patients worldwide.

The company boasts modern production facilities in various locations, including China and the United States, equipped with advanced manufacturing technologies that comply with international Good Manufacturing Practice (GMP) standards. These facilities enable Hepalink to maintain a sustainable and stable supply of high-quality products, including heparin and biopharmaceuticals. Additionally, Hepalink is involved in Contract Development and Manufacturing Organization (CDMO) services, focusing on recombinant biopharmaceuticals and gene therapy products. The company has made significant strides in the biopharmaceutical sector, including the production of monoclonal antibodies and mRNA vaccine components, showcasing its innovative capabilities and commitment to advancing healthcare solutions.

China

Established in 1998 in Shenzhen, China, Hepalink is a leading multinational biopharmaceutical company dual-listed in Hong Kong and mainland China, with its core business in heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs.

These three synergistic business segments are driven by the mission of addressing patients' unmet medical needs and bringing safe and effective therapies and services to patients around the world.

Hepalink Group

Company Details